Annual Total Long Term Liabilities
$15.83 M
+$10.98 M+226.13%
December 31, 2023
Summary
- As of February 8, 2025, SABS annual total long term liabilities is $15.83 million, with the most recent change of +$10.98 million (+226.13%) on December 31, 2023.
- During the last 3 years, SABS annual total long term liabilities has risen by +$9.36 million (+144.71%).
- SABS annual total long term liabilities is now -1.90% below its all-time high of $16.14 million, reached on December 31, 2021.
Performance
SABS Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Long Term Liabilities
$8.08 M
-$141.70 K-1.72%
September 30, 2024
Summary
- As of February 8, 2025, SABS quarterly total long term liabilities is $8.08 million, with the most recent change of -$141.70 thousand (-1.72%) on September 30, 2024.
- Over the past year, SABS quarterly long term liabilities has increased by +$4.21 million (+108.77%).
- SABS quarterly long term liabilities is now -49.93% below its all-time high of $16.14 million, reached on December 31, 2021.
Performance
SABS Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Long Term Liabilities Formula
Long-Term Liabilities = Long-Term Debt + Deferred Tax Liabilities + Pension Liabilities + Other Long-Term Liabilities
SABS Long Term Liabilities Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +226.1% | +108.8% |
3 y3 years | +144.7% | +68.9% |
5 y5 years | +0.9% | +68.9% |
SABS Long Term Liabilities Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3-year | -1.9% | +226.1% | -49.9% | +108.8% |
5 y | 5-year | -1.9% | +226.1% | -49.9% | +108.8% |
alltime | all time | -1.9% | +226.1% | -49.9% | +108.8% |
SAB Biotherapeutics Long Term Liabilities History
Date | Annual | Quarterly |
---|---|---|
Sep 2024 | - | $8.08 M(-1.7%) |
Jun 2024 | - | $8.22 M(-19.8%) |
Mar 2024 | - | $10.24 M(-35.3%) |
Dec 2023 | $15.83 M(+226.1%) | $15.83 M(+309.1%) |
Sep 2023 | - | $3.87 M(-17.9%) |
Jun 2023 | - | $4.72 M(+2.4%) |
Mar 2023 | - | $4.60 M(-5.1%) |
Dec 2022 | $4.85 M | $4.85 M(+1.5%) |
Date | Annual | Quarterly |
---|---|---|
Sep 2022 | - | $4.78 M(-18.9%) |
Jun 2022 | - | $5.90 M(-25.9%) |
Mar 2022 | - | $7.96 M(-50.7%) |
Dec 2021 | $16.14 M(+149.5%) | $16.14 M(+65.5%) |
Sep 2021 | - | $9.75 M(+69.4%) |
Jun 2021 | - | $5.76 M(-11.0%) |
Dec 2020 | $6.47 M(-58.8%) | $6.47 M |
Dec 2019 | $15.69 M | - |
FAQ
- What is SAB Biotherapeutics annual total long term liabilities?
- What is the all time high annual total long term liabilities for SAB Biotherapeutics?
- What is SAB Biotherapeutics annual total long term liabilities year-on-year change?
- What is SAB Biotherapeutics quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for SAB Biotherapeutics?
- What is SAB Biotherapeutics quarterly long term liabilities year-on-year change?
What is SAB Biotherapeutics annual total long term liabilities?
The current annual total long term liabilities of SABS is $15.83 M
What is the all time high annual total long term liabilities for SAB Biotherapeutics?
SAB Biotherapeutics all-time high annual total long term liabilities is $16.14 M
What is SAB Biotherapeutics annual total long term liabilities year-on-year change?
Over the past year, SABS annual total long term liabilities has changed by +$10.98 M (+226.13%)
What is SAB Biotherapeutics quarterly total long term liabilities?
The current quarterly long term liabilities of SABS is $8.08 M
What is the all time high quarterly long term liabilities for SAB Biotherapeutics?
SAB Biotherapeutics all-time high quarterly total long term liabilities is $16.14 M
What is SAB Biotherapeutics quarterly long term liabilities year-on-year change?
Over the past year, SABS quarterly total long term liabilities has changed by +$4.21 M (+108.77%)